



DEC 20 1999

HFI-35
11331811

WARNING LETTER

**CERTIFIED MAIL
RETURN RECEIPT**

Karen Lindner
President
Danmar Products, Inc.
221 Jackson Industrial Dr.
Ann Arbor, MI 48103

Dear Ms. Lindner:

We are writing to you because information we received from you by letter dated October 30, 1999, and from other sources, revealed a serious regulatory problem involving the product known as the cranial helmet, that is made and marketed by your firm.

Under a United States Federal law, the Federal Food, Drug, and Cosmetic Act (the Act), this product is considered to be a medical device because it is used to diagnose or treat a medical condition or to affect the structure or function of the body. The law requires that manufacturers of medical devices obtain marketing clearance for their products from FDA before they may offer them for sale. This helps protect the public health by ensuring that new medical devices are shown to be either safe and effective or substantially equivalent to other devices already legally marketed in this country.

Our records do not show that you obtained marketing clearance before you began offering your product for sale. The kind of information you need to submit in order to obtain this clearance is described in the enclosed materials. The FDA will evaluate this information and decide whether your product may be legally marketed.

Because you do not have marketing clearance from FDA, marketing your product is a violation of the law. In legal terms, the product is adulterated under section 501 (f) (1) (B) and misbranded under section 502(o) of the Act. Your product is adulterated under the Act because you did not obtain premarket approval based on information developed by you that shows your device is safe and effective. Your product is misbranded under the Act because you did not submit information that shows your device is substantially equivalent to other devices that are legally marketed.

You should know that this serious violation of the law may result in FDA taking regulatory actions without further notice to you. These actions may include, but are not limited to, seizing your product inventory, obtaining a court injunction against further

marketing of the product, or assessing civil money penalties. Also, other Federal agencies are informed about the warning letters we issue, such as this one, so that they may consider this information when awarding government contracts.

It is necessary for you to take action on this matter now. Please let this office know in writing within fifteen (15) working days from the date you received this letter what steps you are taking to correct the problem. We also ask that you explain how you plan to prevent this from happening again. If you need more time, let us know why and when you expect to complete your correction. Please direct your response to:

James W. Eisele, Consumer Safety Officer
Office of Compliance
Division of Enforcement III (HFZ-343)
Center for Devices and Radiological Health
2094 Gaither Rd.
Rockville, MD 20850

Finally, you should understand that there are many FDA requirements pertaining to the manufacture and marketing of medical devices. This letter pertains only to the issue of premarket clearance for your device and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for manufacturers of medical devices by contacting our Division of Small Manufacturers Assistance at 1-(800) 638-2041 or through the Internet at <http://www.fda.gov>.

If you have more specific questions about how FDA marketing requirements affect your particular device, or about the content of this letter, please feel free to contact Mr. Eisele at (301) 594 – 4659.

Sincerely yours,

A handwritten signature in black ink that reads "Lillian J. Gill". The signature is written in a cursive style with a large initial "L".

Lillian J. Gill
Director
Office of Compliance
Center for Devices and
Radiological Health

Enclosure